Blog
RSS FeedPosted by Michael Wonder on 15 Apr 2021
Bristol Myers Squibb receives European Commission approval for Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) as first-line treatment for patients with advanced renal cell carcinoma
14 April 2021 - Approval based on Phase 3 CheckMate-9ER trial results showing Opdivo in combination with Cabometyx significantly improved overall ...
Posted by Michael Wonder on 15 Apr 2021
Public consultation – draft 2021-22 Cost Recovery Implementation Statement for listing medicines on the PBS and designated vaccines on the NIP
15 April 2021 - Consultation on the content of the draft Cost Recovery Implementation Statement for listing medicines on the ...
Posted by Michael Wonder on 14 Apr 2021
Petition filed for better access to haemophilia A drug
14 April 2021 - Parents of paediatric patients with haemophilia A are demanding the regulator to change the criteria for ...
Posted by Michael Wonder on 14 Apr 2021
Moleculin awarded new rare paediatric disease designation from U.S. FDA for WP1066 for the treatment of ependymoma
14 April 2021 - Moleculin Biotech announced today that the U.S. FDA has granted rare paediatric disease designation to its ...
Posted by Michael Wonder on 14 Apr 2021
TGA grants provisional determination to GSK for COVID-19 monoclonal antibody treatment - sotrovimab
14 April 2021 - The TGA has granted a provisional determination to GSK in relation to the monoclonal antibody treatment, ...
Posted by Michael Wonder on 14 Apr 2021
Tagrisso approved in China in early lung cancer
14 April 2021 - Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk ...
Posted by Michael Wonder on 14 Apr 2021
Easier access to rare metabolic disorder treatments
14 April 2021 - PHARMAC is making it easier for clinicians to access six treatments for rare metabolic disorders for ...
Posted by Michael Wonder on 13 Apr 2021
Atossa Therapeutics announces ovarian cancer patient has begun treatment with oral endoxifen under FDA’s Expanded Access Pathway
13 April 2021 - Atossa Therapeutics today announced that an ovarian cancer patient has begun treatment with Atossa’s proprietary oral endoxifen. ...
Posted by Michael Wonder on 13 Apr 2021
New recommendations on the critical appraisal of systematic reviews with cost and cost effectiveness outcomes
13 April 2021 - ISPOR announced today the publication of new guidance on how to evaluate the quality and risk ...
Posted by Michael Wonder on 13 Apr 2021
Scotland opens door to Translarna for Duchenne muscular dystrophy
13 April 2021 - A disparity in UK access to a medicine for Duchenne muscular dystrophy has been addressed, after ...
Posted by Michael Wonder on 13 Apr 2021
Qilian International announces inclusion of 16 products into China's National Reimbursement Drugs List
13 April 2021 - Qilian International today announced that 16 of its products have been included in the latest version of ...
Posted by Michael Wonder on 13 Apr 2021
Europe tries to lower drug prices with small doses of transparency
13 April 2021 - For countries in Europe, negotiating a deal with a pharma company over drug prices is the ...
Posted by Michael Wonder on 13 Apr 2021
Four medicines accepted for use by NHS Scotland
13 April 2021 - The Scottish Medicines Consortium has approved NHS funding for four new medicines, including treatments for multiple ...
Posted by Michael Wonder on 13 Apr 2021
FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer
13 April 2021 - Today the Food and Drug Administration granted accelerated approval to sacituzumab govitecan (Trodelvy, Immunomedics) for patients ...
Posted by Michael Wonder on 13 Apr 2021
vTv Therapeutics receives FDA breakthrough therapy designation for TTP399 for the treatment of type 1 diabetes
13 April 2021 - Designation offers potential for expedited development pathway and reinforces TTP399’s potential to provide a substantial clinical benefit. ...